Myocardial infarction as a predictor of diffuse large B cell lymphoma?

    Authors

    Keywords

    lymphoma, myocardial infarction

    DOI

    https://doi.org/10.15836/ccar2024.111

    Full Text

    Introduction: Patients with cancer have an increased risk of both venous and arterial thromboembolism (AT) ( 1 ). Aggressive lymphomas like the most common type - diffuse large B cell lymphoma (DLBCL) have a higher frequency of AT compared to indolent ones after diagnosis and during treatment ( 2 , 3 ). However there is little information about the frequency of AT such as myocardial infarction (MI) before the diagnosis of DLBCL. Aim: To determine the prevalence of MI in DLBCL before diagnosis. Patients and Methods: We collected data retrospectively from DLBCL patients at the General Hospital Dr. Josip Benčević from the beginning of 2011 by August 2023. Results: 59 DLBCL patients were included in this study, 33 (56%) female, median age 67 (range 28 to 82 years). Eight (13.6%) patients had MI before the DLBCL diagnosis, 6 male and 2 female. All eight patients who had a MI achieved a complete remission (CR) of the DLBCL after the planned treatment (4 patients treated with R CHOP and 4 with DA R EPOCH protocol). Seven patients are alive, with no signs of DLBCL, and 1 patient died 8 years after the end of treatment at the age of 84. The rate of CR in the entire study population was 83% after first line of treatment and 47 (63%) patients are still alive in CR. 6 patients died of DLBCL, 8 of infectious complications, while the cause of death for 8 patients is unknown. 2 patients had MI after diagnosis of DLBCL. One 5 years after the completion of chemotherapy and he previously had an MI, while the other patient developed an MI at the time of relapse of DLBCL. Conclusions: Our study suggests a higher prevalence of IM in patients with DLBCL (13.6%) than in general population (3.8%) ( 4 ). Interestingly in our study is the fact that a previous MI did not negatively affect the outcome of treatment. The group of patients with a previous MI actually had a better survival compared to the entire study population. Further studies with more patients are needed to confirm this observation, and eventually to find a link between DLBCL and MI.

    Cardiologia Croatica
    Back to search

    Myocardial infarction as a predictor of diffuse large B cell lymphoma?

    Extended Abstract
    Issue3-4
    Published
    Pages111
    PDF via DOIhttps://doi.org/10.15836/ccar2024.111
    lymphoma
    myocardial infarction

    Authors

    Hrvoje Holik*ORCIDGeneral Hospital “Dr. Josip Benčević”, Slavonski Brod, Croatia
    Ivana Vučinić LjubičićORCIDGeneral Hospital “Dr. Josip Benčević”, Slavonski Brod, Croatia
    Božena CohaORCIDGeneral Hospital “Dr. Josip Benčević”, Slavonski Brod, Croatia

    Full Text

    Introduction: Patients with cancer have an increased risk of both venous and arterial thromboembolism (AT) ( 1 ). Aggressive lymphomas like the most common type - diffuse large B cell lymphoma (DLBCL) have a higher frequency of AT compared to indolent ones after diagnosis and during treatment ( 2 , 3 ). However there is little information about the frequency of AT such as myocardial infarction (MI) before the diagnosis of DLBCL. Aim: To determine the prevalence of MI in DLBCL before diagnosis. Patients and Methods: We collected data retrospectively from DLBCL patients at the General Hospital Dr. Josip Benčević from the beginning of 2011 by August 2023. Results: 59 DLBCL patients were included in this study, 33 (56%) female, median age 67 (range 28 to 82 years). Eight (13.6%) patients had MI before the DLBCL diagnosis, 6 male and 2 female. All eight patients who had a MI achieved a complete remission (CR) of the DLBCL after the planned treatment (4 patients treated with R CHOP and 4 with DA R EPOCH protocol). Seven patients are alive, with no signs of DLBCL, and 1 patient died 8 years after the end of treatment at the age of 84. The rate of CR in the entire study population was 83% after first line of treatment and 47 (63%) patients are still alive in CR. 6 patients died of DLBCL, 8 of infectious complications, while the cause of death for 8 patients is unknown. 2 patients had MI after diagnosis of DLBCL. One 5 years after the completion of chemotherapy and he previously had an MI, while the other patient developed an MI at the time of relapse of DLBCL. Conclusions: Our study suggests a higher prevalence of IM in patients with DLBCL (13.6%) than in general population (3.8%) ( 4 ). Interestingly in our study is the fact that a previous MI did not negatively affect the outcome of treatment. The group of patients with a previous MI actually had a better survival compared to the entire study population. Further studies with more patients are needed to confirm this observation, and eventually to find a link between DLBCL and MI.